Institutional ticker directory tracking stock mentions, long/short ideas, and high-conviction pitches extracted from quarterly hedge fund letters.
| Ticker | Company | Sector | Industry | Pitches | Stance |
|---|---|---|---|---|---|
| Fund / Manager | Thesis Excerpt | Stance | Period / Date | Action |
|---|---|---|---|---|
Minot Light Capital Partners Tom Wetherald and Eddie Reilly | “As a side note, we were actually able to more than make-up for our XOMA losses in the days following the disappointment. On the day of its adverse data read-out, XOMA's partner, Rezolute (RZLT), fell over 90% and traded well below net cash value, despite having another potential billion dollar indication in its pipeline. We were able to purchase shares of RZLT that morning. The stock has more than doubled from our cost-basis in short order. This rapid recovery validated our view that the sell-off was indiscriminate and disconnected from long-term value. BSD Analysis: Rezolute is a clinical-stage biotech targeting rare metabolic disorders with high unmet need. The science is promising, but outcomes remain binary. Clinical execution and regulatory clarity will determine everything. Cash runway is a constant concern. Investors price in failure aggressively. If data validates efficacy, upside is nonlinear. Commercial potential exists due to orphan pricing dynamics. This is not diversification — it's a bet. Size accordingly.” | BULL | Q4 2025 Jan 15, 2026 | View Pitch |
Each excerpt above is the manager's commentary on this ticker specifically. The full letter has the rest of their portfolio thinking, risk discussion, and broader institutional context.
